Benitec Biopharma Past Earnings Performance
Past criteria checks 0/6
Benitec Biopharma's earnings have been declining at an average annual rate of -24%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 95.8% per year.
Key information
-24.0%
Earnings growth rate
47.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -95.8% |
Return on equity | -32.5% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth
Oct 02Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable
Nov 30Benitec Biopharma prices of $18M securities offering
Sep 13Benitec GAAP EPS of -$2.23, revenue of $0.07M
Sep 02We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
Jan 13We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully
Sep 30Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?
May 12Benitec Bio secures $13M capital via equity offering
Apr 28Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?
Jan 27How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?
Dec 02Revenue & Expenses Breakdown
How Benitec Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -21 | 8 | 15 |
30 Jun 24 | 0 | -22 | 7 | 16 |
31 Mar 24 | 0 | -22 | 6 | 15 |
31 Dec 23 | 0 | -22 | 6 | 16 |
30 Sep 23 | 0 | -21 | 6 | 15 |
30 Jun 23 | 0 | -20 | 6 | 13 |
31 Mar 23 | 0 | -20 | 7 | 13 |
31 Dec 22 | 0 | -19 | 7 | 12 |
30 Sep 22 | 0 | -18 | 7 | 11 |
30 Jun 22 | 0 | -18 | 7 | 11 |
31 Mar 22 | 0 | -17 | 7 | 10 |
31 Dec 21 | 0 | -18 | 6 | 11 |
30 Sep 21 | 0 | -16 | 7 | 9 |
30 Jun 21 | 0 | -14 | 7 | 7 |
31 Mar 21 | 0 | -13 | 7 | 6 |
31 Dec 20 | 0 | -11 | 7 | 4 |
30 Sep 20 | 0 | -10 | 7 | 3 |
30 Jun 20 | 0 | -8 | 6 | 3 |
31 Mar 20 | 1 | -7 | 5 | 3 |
31 Dec 19 | 1 | -6 | 5 | 3 |
30 Sep 19 | 7 | -2 | 4 | 4 |
30 Jun 19 | 12 | 3 | 5 | 5 |
31 Mar 19 | 12 | 2 | 5 | 5 |
31 Dec 18 | 12 | 2 | 6 | 5 |
30 Sep 18 | 8 | -3 | 6 | 5 |
30 Jun 18 | 3 | -9 | 6 | 5 |
31 Mar 18 | 4 | -9 | 7 | 5 |
31 Dec 17 | 6 | -7 | 7 | 5 |
30 Sep 17 | 5 | -7 | 7 | 5 |
30 Jun 17 | 9 | -4 | 7 | 5 |
31 Mar 17 | 7 | -7 | 7 | 6 |
31 Dec 16 | 7 | -8 | 7 | 7 |
30 Sep 16 | 7 | -12 | 9 | 7 |
30 Jun 16 | 3 | -18 | 9 | 10 |
31 Mar 16 | 3 | -18 | 9 | 10 |
31 Dec 15 | 2 | -16 | 8 | 9 |
30 Sep 15 | 2 | -12 | 6 | 8 |
30 Jun 15 | 3 | -9 | 6 | 5 |
31 Mar 15 | 3 | -6 | 5 | 4 |
31 Dec 14 | 1 | -7 | 5 | 3 |
30 Sep 14 | 1 | -7 | 5 | 3 |
30 Jun 14 | 1 | -7 | 5 | 4 |
31 Mar 14 | 1 | -5 | 4 | 3 |
31 Dec 13 | 1 | -3 | 4 | 2 |
Quality Earnings: BNTC is currently unprofitable.
Growing Profit Margin: BNTC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BNTC is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare BNTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BNTC has a negative Return on Equity (-32.5%), as it is currently unprofitable.